Studies Highlight Rapid Expansion of ADHD Drug Prescribing
New studies show rapid expansion of ADHD drug prescribing, with US youth psychiatric drug use rising from 5.3% to 8.3% and Ontario stimulant prescriptions surging 175% during COVID.
Attention Deficit Hyperactivity Disorder
DiseaseAlso known as: ADHD
Related News
FDA Retreats From Artificial Dye Ban, Loosens Labeling Rules on "No Artificial Colors" Claims
The FDA will allow food makers to claim "no artificial colors" as long as dyes are not petroleum-based, even if products contain titanium dioxide. Health experts warn the labeling deceives consumers, as naturally derived additives like titanium dioxide pose health risks and remain unregulated.
New Mental Health Research: Genetics, Diagnosis, and Treatment
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
Otsuka's ADHD Drug Centanafadine Hits Phase 3b Trial Endpoint Ahead of FDA Decision
Otsuka's ADHD drug centanafadine met the primary endpoint in a Phase 3b trial in adults with comorbid anxiety, with results supporting its efficacy ahead of a July 24, 2026 FDA decision. The FDA has granted priority review to the New Drug Application for the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). If approved, centanafadine would be a novel treatment option for ADHD in children, adolescents, and adults.
TGA Warns on Atomoxetine Homicidal Ideation Risk, Publishes February 2026 PI Updates
The TGA warned about the risk of homicidal ideation associated with atomoxetine in paediatric patients and published its February 2026 Product Information safety updates. The updates cover multiple medicines with changes to contraindications, warnings and adverse effects. Nearly one in five Australians took a prescription psychiatric drug in 2023-24.
January and March 2026 drug pipeline updates span Phase 3, Fast Track and Priority Review
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07710014 |
Evaluation of Foquest in Adults 65 Years and Older With ADHD |
NOT_YET_RECRUITING | PHASE4 |
| NCT07678827 |
A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD |
NOT_YET_RECRUITING | PHASE3 |
| NCT07665658 |
Effectiveness of Neuroplasticity-Targeted Supplements on Neuroinflammatory Markers, ADHD Symptom Severity, and Clinical Scores in Children |
RECRUITING | NA |
| NCT07647900 |
Photography-Based Intervention for Children With Attention Deficit Hyperactivity Disorder |
ACTIVE_NOT_RECRUITING | NA |
| NCT07640802 |
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy |
NOT_YET_RECRUITING | |
| NCT07203092 |
Effects of Transcranial Photobiomodulation in ADHD |
RECRUITING | NA |
| NCT07001475 |
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder |
COMPLETED | PHASE1 |
| NCT06847165 |
Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure |
RECRUITING | NA |
| NCT06406309 |
Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD |
COMPLETED | NA |
| NCT06194162 |
Weighted Blankets for Sleep Disturbance Among Children With ADHD |
RECRUITING | NA |